Propanc Biopharma, Inc. (PPCB): EPS (Diluted)

Annual figures by period end, from SEC filings.

Stock splits: 1-for-25, first reflected in a filing dated 2026-07-17. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

-$14.85

Year ended 2025-06-30

2022-06-30 EPS (Diluted) (USD per share) 2025-06-30

Period ended	EPS (Diluted)	Change YoY	Source filing
2025-06-30	-$14.85	n/m	2025-09-29, From 2024-07-01
2024-06-30	-$1420.53	n/m	2025-09-29, From 2023-07-01
2023-06-30	-$1.80	n/m	2024-09-30, From 2022-07-01
2022-06-30	-$49.23	n/a	2023-09-28, From 2021-07-01

EPS (Diluted) at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	EPS (Diluted)	Change YoY
Propanc Biopharma, Inc. (PPCB)	2025-06-30	-$14.85	n/m
Galectin Therapeutics Inc (GALT)	2025-12-31	-$0.48	n/m
Lftd Partners Inc. (LIFD)	2025-12-31	-$1.68	n/m
Marker Therapeutics, Inc. (MRKR)	2025-12-31	-$0.79	n/m
Genelux Corp (GNLX)	2025-12-31	-$0.86	n/m
Evofem Biosciences, Inc. (EVFM)	2025-12-31	$0.00	n/m
Nexentis Technologies Inc. (NXTS)	2025-12-31	-$8.61	n/m
Incannex Healthcare Inc. (IXHL)	2025-06-30	-$1.35	n/m
Galmed Pharmaceuticals Ltd. (EOCN)	2025-12-31	$2.39	-70.4%

Compare PPCB, GALT, LIFD, MRKR side by side · Screen every company in Pharmaceutical Preparations ↗